

INFORMATION ONLY

Fibryga® Product Monograph Changes Customer Letter # 2020-43

2020-10-01

Dear Colleagues:

Please see attached customer letter from Octapharma regarding important changes to the Product Monograph for Fibryga®.

<u>With reference to CL 2020-14 Fibrinogen Concentrate – Educational Resources and Supply</u> we would like to remind our customers that our target brand distribution mix is 60% Fibryga® and 40% RiaSTAP®.

Please share a copy of this customer letter with healthcare professionals at your hospital who might be interested in this information.

This customer letter can also be viewed at www.blood.ca in the "Hospitals Services" section. If you have questions about this letter, or if you require it in an accessible format, please contact your local hospital liaison specialist.

Sincerely,

Sylvain Grenier,

Director, Plasma Protein Products Formulary Program